Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of “Moderate Buy” by Analysts

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has received an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, four have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $15.00.

EPRX has been the topic of several analyst reports. Zacks Research downgraded Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 17th. Cantor Fitzgerald upped their price target on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, January 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Tuesday. Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. Finally, William Blair started coverage on shares of Eupraxia Pharmaceuticals in a research report on Monday, March 23rd. They set an “outperform” rating on the stock.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in EPRX. Guardian Wealth Advisors LLC NC purchased a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at about $76,000. Aptus Capital Advisors LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the fourth quarter valued at about $76,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Eupraxia Pharmaceuticals during the third quarter worth about $71,000. Bank of America Corp DE lifted its stake in shares of Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after acquiring an additional 10,059 shares in the last quarter. Finally, Geode Capital Management LLC acquired a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter worth about $105,000.

Eupraxia Pharmaceuticals Trading Down 1.2%

Shares of NASDAQ EPRX opened at $7.16 on Friday. The stock has a fifty day moving average price of $7.50 and a 200 day moving average price of $7.14. Eupraxia Pharmaceuticals has a 12-month low of $3.67 and a 12-month high of $9.32. The company has a market cap of $432.68 million, a P/E ratio of -6.95 and a beta of 1.55.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21). On average, sell-side analysts forecast that Eupraxia Pharmaceuticals will post -0.71 EPS for the current fiscal year.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.